218 related articles for article (PubMed ID: 28545837)
1. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
Menshykau D
Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
[TBL] [Abstract][Full Text] [Related]
2. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
[TBL] [Abstract][Full Text] [Related]
4. Impact of organ-on-a-chip technology on pharmaceutical R&D costs.
Franzen N; van Harten WH; Retèl VP; Loskill P; van den Eijnden-van Raaij J; IJzerman M
Drug Discov Today; 2019 Sep; 24(9):1720-1724. PubMed ID: 31185290
[TBL] [Abstract][Full Text] [Related]
5. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics.
Grime KH; Barton P; McGinnity DF
Mol Pharm; 2013 Apr; 10(4):1191-206. PubMed ID: 23253040
[TBL] [Abstract][Full Text] [Related]
6. Hit discovery and hit-to-lead approaches.
Keseru GM; Makara GM
Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
[TBL] [Abstract][Full Text] [Related]
7. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
8. The impact of systems approaches on biological problems in drug discovery.
Hood L; Perlmutter RM
Nat Biotechnol; 2004 Oct; 22(10):1215-7. PubMed ID: 15470453
[No Abstract] [Full Text] [Related]
9. HTS technologies in biopharmaceutical discovery.
Wu G; Doberstein SK
Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the preclinical/clinical interface: an Informa Life Sciences conference 12-13 December, 2006, London, UK.
Cavero I
Expert Opin Drug Saf; 2007 Mar; 6(2):217-24. PubMed ID: 17367268
[TBL] [Abstract][Full Text] [Related]
11. Translational research in central nervous system drug discovery.
Hurko O; Ryan JL
NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
[TBL] [Abstract][Full Text] [Related]
12. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
13. In vitro models for evaluating safety and efficacy of novel technologies for skin drug delivery.
Planz V; Lehr CM; Windbergs M
J Control Release; 2016 Nov; 242():89-104. PubMed ID: 27612408
[TBL] [Abstract][Full Text] [Related]
14. High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.
Conant G; Lai BFL; Lu RXZ; Korolj A; Wang EY; Radisic M
Stem Cell Rev Rep; 2017 Jun; 13(3):335-346. PubMed ID: 28429185
[TBL] [Abstract][Full Text] [Related]
15. Effective integration of systems biology, biomarkers, biosimulation and modelling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
Eur J Pharm Sci; 2007 May; 31(1):62-7. PubMed ID: 17408933
[TBL] [Abstract][Full Text] [Related]
16. Extrapolation of preclinical data into clinical reality translational science.
Singer T
Ernst Schering Res Found Workshop; 2007; (59):1-5. PubMed ID: 17117711
[TBL] [Abstract][Full Text] [Related]
17. Emerging technologies and challenges for better and safer drugs.
Theodosiou M; Amir-Aslani A; Mégarbane B
Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
[TBL] [Abstract][Full Text] [Related]
18. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
Donato MT; Gómez-Lechón MJ; Tolosa L
Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
[TBL] [Abstract][Full Text] [Related]
19. Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.
Ewart L; Fabre K; Chakilam A; Dragan Y; Duignan DB; Eswaraka J; Gan J; Guzzie-Peck P; Otieno M; Jeong CG; Keller DA; de Morais SM; Phillips JA; Proctor W; Sura R; Van Vleet T; Watson D; Will Y; Tagle D; Berridge B
Exp Biol Med (Maywood); 2017 Oct; 242(16):1579-1585. PubMed ID: 28622731
[TBL] [Abstract][Full Text] [Related]
20. MRI in preclinical drug development.
Silva MD; Chandra S
Methods Mol Med; 2006; 124():299-322. PubMed ID: 16506427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
